Drugs / REC-994
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05085561 Comparator | Mar 2022 → Jun 2025 | cerebral cavernous malformation | Recursion Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REC-994 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05085561 ↗ |